Erik Zeegen, MD
Orthopaedic Surgery · Tarzana, CANPI 1427039437
Payments from drug & device makers
Across 265 payments — averaging $1544.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$383K
- Smith+Nephew$13K
- Medical Device Business Services, Inc.$9K
- Johnson & Johnson$3K
- Stryker$133
- Siemens Medical Solutions USA, Inc.$120
- plus $74 from 4 others
What the payments were for
- Royalty or licence$72,52718%
- Consulting fees$135,34733%
- Speaking & faculty fees$10,9383%
- Travel & lodging$35,3819%
- Food & beverage$4,3421%
- Education$150,70537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 237 | $383,276 |
| Smith+Nephew | 14 | $13,105 |
| Medical Device Business Services, Inc. | 2 | $9,164 |
| Johnson & Johnson(2 entities) | 6 | $3,369 |
| Stryker | 1 | $133 |
| Siemens Medical Solutions USA, Inc. | 1 | $120 |
| Innovation Technologies Inc | 1 | $37 |
| Heron Therapeutics, Inc. | 1 | $22 |
| Dynasplint Systems Inc. | 1 | $15 |
| Radlink, Inc | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona$120,029
- ROSA$90,312
- Z1 HIP SYSTEM$72,527
- Avenir$49,235
- G7$24,431
- ROSA-Knee$17,078
- DERMABOND$12,340
- Arcos$12,125
- Journey II XR$11,438
- Journey II$10,938
- Journey II BCS$10,938
- Journey II CR$10,938
- STRATAFIX$9,315
- SURGICEL NU-KNIT$9,072
- VISTASEAL$9,072
- Persona Revision$6,500
- Taperloc$6,500
- NexGen$2,750
- mymobility Platform$1,750
- REDAPT$832
How this compares
$409,239 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 28 | $595 |
| Gabapentin | 14 | $459 |
| Meloxicam | 107 | $340 |
| Amoxicillin | 180 | $283 |
| Oxycodone Hcl | 18 | $144 |
| Cephalexin | 12 | $115 |
| Clindamycin Hcl | 17 | $86 |
| Tramadol Hcl | 16 | $84 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Tarzana
- Bradford HackArcadia$18.3M
- Robert GorabOrange$14.5M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
- Thomas CoonRed Bluff$9.2M
- Peter NewtonSan Diego$7M
- Nirav AminPlacentia$5.8M
- Tom NorrisSan Francisco$5.3M
- Jay LiebermanLos Angeles$4.8M
- Sigurd BervenSan Francisco$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.